Advertisement


Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab

EHA 2021 Virtual Congress

Advertisement

Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses a primary analysis of the phase III GLOW study, which, for the first time, compared the efficacy and safety of fixed-duration ibrutinib plus venetoclax with chlorambucil plus obinutuzumab for first-line treatment of older patients with chronic lymphocytic leukemia (LB1902).



Related Videos

Lymphoma

Gaurav Goyal, MD, on DLBCL: Comparing R-CHOP and R-EPOCH for Overall Survival Benefits

Gaurav Goyal, MD, of the University of Alabama at Birmingham, reports on findings from a large multi-institutional database study, which showed there was no apparent difference in overall survival between R-CHOP and R-EPOCH among patients with advanced-stage MYC-rearranged, double-hit, or triple-hit diffuse large B-cell lymphoma. Further studies are needed for better risk stratification to optimize outcomes (Abstract S224).

Leukemia

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).

Lymphoma
Immunotherapy

Martin Hutchings, MD, PhD, on Hodgkin Lymphoma: Brentuximab Vedotin With Chemotherapy

Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).

Multiple Myeloma
Leukemia

Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy

Martin Kaiser, MD, of The Institute of Cancer Research and Royal Marsden Hospital, discusses findings from the UK OPTIMUM/MUKNINE trial on the depth of response and minimal residual disease status in patients with ultra-high–risk newly diagnosed multiple myeloma and plasma cell leukemia who were treated with augmented autologous transplant and daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone (Abstract S181).

Multiple Myeloma
Immunotherapy

Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation

Philippe Moreau, MD, of University Hospital Hôtel-Dieu, discusses findings from the CASSIOPEIA trial, Part 1, on daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma who have been treated with bortezomib, thalidomide, and dexamethasone, with or without daratumumab, and autologous stem cell transplantation (Abstract S180).

Advertisement

Advertisement




Advertisement